Rethinking the role of hydroxychloroquine in the treatment of COVID-19.
Identifieur interne : 001836 ( Main/Corpus ); précédent : 001835; suivant : 001837Rethinking the role of hydroxychloroquine in the treatment of COVID-19.
Auteurs : Eric A. Meyerowitz ; Augustin G L. Vannier ; Morgan G N. Friesen ; Sara Schoenfeld ; Jeffrey A. Gelfand ; Michael V. Callahan ; Arthur Y. Kim ; Patrick M. Reeves ; Mark C. PoznanskySource :
- FASEB journal : official publication of the Federation of American Societies for Experimental Biology [ 1530-6860 ] ; 2020.
English descriptors
- KwdEn :
- COVID-19 (MeSH), Coronavirus Infections (drug therapy), Datasets as Topic (standards), Heart (drug effects), Humans (MeSH), Hydroxychloroquine (adverse effects), Hydroxychloroquine (pharmacology), Hydroxychloroquine (therapeutic use), Immunity, Innate (drug effects), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Randomized Controlled Trials as Topic (standards).
- MESH :
- chemical , adverse effects : Hydroxychloroquine.
- drug effects : Heart, Immunity, Innate.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- chemical , pharmacology : Hydroxychloroquine.
- standards : Datasets as Topic, Randomized Controlled Trials as Topic.
- chemical , therapeutic use : Hydroxychloroquine.
- COVID-19, Humans, Pandemics.
Abstract
There are currently no proven or approved treatments for coronavirus disease 2019 (COVID-19). Early anecdotal reports and limited in vitro data led to the significant uptake of hydroxychloroquine (HCQ), and to lesser extent chloroquine (CQ), for many patients with this disease. As an increasing number of patients with COVID-19 are treated with these agents and more evidence accumulates, there continues to be no high-quality clinical data showing a clear benefit of these agents for this disease. Moreover, these agents have the potential to cause harm, including a broad range of adverse events including serious cardiac side effects when combined with other agents. In addition, the known and potent immunomodulatory effects of these agents which support their use in the treatment of auto-immune conditions, and provided a component in the original rationale for their use in patients with COVID-19, may, in fact, undermine their utility in the context of the treatment of this respiratory viral infection. Specifically, the impact of HCQ on cytokine production and suppression of antigen presentation may have immunologic consequences that hamper innate and adaptive antiviral immune responses for patients with COVID-19. Similarly, the reported in vitro inhibition of viral proliferation is largely derived from the blockade of viral fusion that initiates infection rather than the direct inhibition of viral replication as seen with nucleoside/tide analogs in other viral infections. Given these facts and the growing uncertainty about these agents for the treatment of COVID-19, it is clear that at the very least thoughtful planning and data collection from randomized clinical trials are needed to understand what if any role these agents may have in this disease. In this article, we review the datasets that support or detract from the use of these agents for the treatment of COVID-19 and render a data informed opinion that they should only be used with caution and in the context of carefully thought out clinical trials, or on a case-by-case basis after rigorous consideration of the risks and benefits of this therapeutic approach.
DOI: 10.1096/fj.202000919
PubMed: 32350928
PubMed Central: PMC7267640
Links to Exploration step
pubmed:32350928Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rethinking the role of hydroxychloroquine in the treatment of COVID-19.</title><author><name sortKey="Meyerowitz, Eric A" sort="Meyerowitz, Eric A" uniqKey="Meyerowitz E" first="Eric A" last="Meyerowitz">Eric A. Meyerowitz</name><affiliation><nlm:affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Vannier, Augustin G L" sort="Vannier, Augustin G L" uniqKey="Vannier A" first="Augustin G L" last="Vannier">Augustin G L. Vannier</name><affiliation><nlm:affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Vaccine and Immunotherapy Center (VIC), MGH and HMS, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Friesen, Morgan G N" sort="Friesen, Morgan G N" uniqKey="Friesen M" first="Morgan G N" last="Friesen">Morgan G N. Friesen</name><affiliation><nlm:affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Vaccine and Immunotherapy Center (VIC), MGH and HMS, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Schoenfeld, Sara" sort="Schoenfeld, Sara" uniqKey="Schoenfeld S" first="Sara" last="Schoenfeld">Sara Schoenfeld</name><affiliation><nlm:affiliation>Division of Allergy, Immunology and Rheumatology, MGH and HMS, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Gelfand, Jeffrey A" sort="Gelfand, Jeffrey A" uniqKey="Gelfand J" first="Jeffrey A" last="Gelfand">Jeffrey A. Gelfand</name><affiliation><nlm:affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Vaccine and Immunotherapy Center (VIC), MGH and HMS, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Callahan, Michael V" sort="Callahan, Michael V" uniqKey="Callahan M" first="Michael V" last="Callahan">Michael V. Callahan</name><affiliation><nlm:affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Vaccine and Immunotherapy Center (VIC), MGH and HMS, Boston, MA, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Special Advisor to the Assistant Secretary of Public Health Preparedness and Response U.S Dept of Health and Human Services, Washington, DC, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Arthur Y" sort="Kim, Arthur Y" uniqKey="Kim A" first="Arthur Y" last="Kim">Arthur Y. Kim</name><affiliation><nlm:affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Reeves, Patrick M" sort="Reeves, Patrick M" uniqKey="Reeves P" first="Patrick M" last="Reeves">Patrick M. Reeves</name><affiliation><nlm:affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Vaccine and Immunotherapy Center (VIC), MGH and HMS, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Poznansky, Mark C" sort="Poznansky, Mark C" uniqKey="Poznansky M" first="Mark C" last="Poznansky">Mark C. Poznansky</name><affiliation><nlm:affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Vaccine and Immunotherapy Center (VIC), MGH and HMS, Boston, MA, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32350928</idno><idno type="pmid">32350928</idno><idno type="doi">10.1096/fj.202000919</idno><idno type="pmc">PMC7267640</idno><idno type="wicri:Area/Main/Corpus">001836</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001836</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Rethinking the role of hydroxychloroquine in the treatment of COVID-19.</title><author><name sortKey="Meyerowitz, Eric A" sort="Meyerowitz, Eric A" uniqKey="Meyerowitz E" first="Eric A" last="Meyerowitz">Eric A. Meyerowitz</name><affiliation><nlm:affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Vannier, Augustin G L" sort="Vannier, Augustin G L" uniqKey="Vannier A" first="Augustin G L" last="Vannier">Augustin G L. Vannier</name><affiliation><nlm:affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Vaccine and Immunotherapy Center (VIC), MGH and HMS, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Friesen, Morgan G N" sort="Friesen, Morgan G N" uniqKey="Friesen M" first="Morgan G N" last="Friesen">Morgan G N. Friesen</name><affiliation><nlm:affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Vaccine and Immunotherapy Center (VIC), MGH and HMS, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Schoenfeld, Sara" sort="Schoenfeld, Sara" uniqKey="Schoenfeld S" first="Sara" last="Schoenfeld">Sara Schoenfeld</name><affiliation><nlm:affiliation>Division of Allergy, Immunology and Rheumatology, MGH and HMS, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Gelfand, Jeffrey A" sort="Gelfand, Jeffrey A" uniqKey="Gelfand J" first="Jeffrey A" last="Gelfand">Jeffrey A. Gelfand</name><affiliation><nlm:affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Vaccine and Immunotherapy Center (VIC), MGH and HMS, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Callahan, Michael V" sort="Callahan, Michael V" uniqKey="Callahan M" first="Michael V" last="Callahan">Michael V. Callahan</name><affiliation><nlm:affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Vaccine and Immunotherapy Center (VIC), MGH and HMS, Boston, MA, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Special Advisor to the Assistant Secretary of Public Health Preparedness and Response U.S Dept of Health and Human Services, Washington, DC, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Arthur Y" sort="Kim, Arthur Y" uniqKey="Kim A" first="Arthur Y" last="Kim">Arthur Y. Kim</name><affiliation><nlm:affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Reeves, Patrick M" sort="Reeves, Patrick M" uniqKey="Reeves P" first="Patrick M" last="Reeves">Patrick M. Reeves</name><affiliation><nlm:affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Vaccine and Immunotherapy Center (VIC), MGH and HMS, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Poznansky, Mark C" sort="Poznansky, Mark C" uniqKey="Poznansky M" first="Mark C" last="Poznansky">Mark C. Poznansky</name><affiliation><nlm:affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Vaccine and Immunotherapy Center (VIC), MGH and HMS, Boston, MA, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">FASEB journal : official publication of the Federation of American Societies for Experimental Biology</title><idno type="eISSN">1530-6860</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Datasets as Topic (standards)</term><term>Heart (drug effects)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (adverse effects)</term><term>Hydroxychloroquine (pharmacology)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Immunity, Innate (drug effects)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Randomized Controlled Trials as Topic (standards)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Heart</term><term>Immunity, Innate</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Datasets as Topic</term><term>Randomized Controlled Trials as Topic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>COVID-19</term><term>Humans</term><term>Pandemics</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There are currently no proven or approved treatments for coronavirus disease 2019 (COVID-19). Early anecdotal reports and limited in vitro data led to the significant uptake of hydroxychloroquine (HCQ), and to lesser extent chloroquine (CQ), for many patients with this disease. As an increasing number of patients with COVID-19 are treated with these agents and more evidence accumulates, there continues to be no high-quality clinical data showing a clear benefit of these agents for this disease. Moreover, these agents have the potential to cause harm, including a broad range of adverse events including serious cardiac side effects when combined with other agents. In addition, the known and potent immunomodulatory effects of these agents which support their use in the treatment of auto-immune conditions, and provided a component in the original rationale for their use in patients with COVID-19, may, in fact, undermine their utility in the context of the treatment of this respiratory viral infection. Specifically, the impact of HCQ on cytokine production and suppression of antigen presentation may have immunologic consequences that hamper innate and adaptive antiviral immune responses for patients with COVID-19. Similarly, the reported in vitro inhibition of viral proliferation is largely derived from the blockade of viral fusion that initiates infection rather than the direct inhibition of viral replication as seen with nucleoside/tide analogs in other viral infections. Given these facts and the growing uncertainty about these agents for the treatment of COVID-19, it is clear that at the very least thoughtful planning and data collection from randomized clinical trials are needed to understand what if any role these agents may have in this disease. In this article, we review the datasets that support or detract from the use of these agents for the treatment of COVID-19 and render a data informed opinion that they should only be used with caution and in the context of carefully thought out clinical trials, or on a case-by-case basis after rigorous consideration of the risks and benefits of this therapeutic approach.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32350928</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-6860</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>05</Month></PubDate></JournalIssue><Title>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</Title><ISOAbbreviation>FASEB J</ISOAbbreviation></Journal><ArticleTitle>Rethinking the role of hydroxychloroquine in the treatment of COVID-19.</ArticleTitle><Pagination><MedlinePgn>6027-6037</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1096/fj.202000919</ELocationID><Abstract><AbstractText>There are currently no proven or approved treatments for coronavirus disease 2019 (COVID-19). Early anecdotal reports and limited in vitro data led to the significant uptake of hydroxychloroquine (HCQ), and to lesser extent chloroquine (CQ), for many patients with this disease. As an increasing number of patients with COVID-19 are treated with these agents and more evidence accumulates, there continues to be no high-quality clinical data showing a clear benefit of these agents for this disease. Moreover, these agents have the potential to cause harm, including a broad range of adverse events including serious cardiac side effects when combined with other agents. In addition, the known and potent immunomodulatory effects of these agents which support their use in the treatment of auto-immune conditions, and provided a component in the original rationale for their use in patients with COVID-19, may, in fact, undermine their utility in the context of the treatment of this respiratory viral infection. Specifically, the impact of HCQ on cytokine production and suppression of antigen presentation may have immunologic consequences that hamper innate and adaptive antiviral immune responses for patients with COVID-19. Similarly, the reported in vitro inhibition of viral proliferation is largely derived from the blockade of viral fusion that initiates infection rather than the direct inhibition of viral replication as seen with nucleoside/tide analogs in other viral infections. Given these facts and the growing uncertainty about these agents for the treatment of COVID-19, it is clear that at the very least thoughtful planning and data collection from randomized clinical trials are needed to understand what if any role these agents may have in this disease. In this article, we review the datasets that support or detract from the use of these agents for the treatment of COVID-19 and render a data informed opinion that they should only be used with caution and in the context of carefully thought out clinical trials, or on a case-by-case basis after rigorous consideration of the risks and benefits of this therapeutic approach.</AbstractText><CopyrightInformation>© 2020 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meyerowitz</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vannier</LastName><ForeName>Augustin G L</ForeName><Initials>AGL</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine and Immunotherapy Center (VIC), MGH and HMS, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friesen</LastName><ForeName>Morgan G N</ForeName><Initials>MGN</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine and Immunotherapy Center (VIC), MGH and HMS, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schoenfeld</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Allergy, Immunology and Rheumatology, MGH and HMS, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelfand</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine and Immunotherapy Center (VIC), MGH and HMS, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callahan</LastName><ForeName>Michael V</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine and Immunotherapy Center (VIC), MGH and HMS, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Special Advisor to the Assistant Secretary of Public Health Preparedness and Response U.S Dept of Health and Human Services, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Arthur Y</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reeves</LastName><ForeName>Patrick M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine and Immunotherapy Center (VIC), MGH and HMS, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poznansky</LastName><ForeName>Mark C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine and Immunotherapy Center (VIC), MGH and HMS, Boston, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>FASEB J</MedlineTA><NlmUniqueID>8804484</NlmUniqueID><ISSNLinking>0892-6638</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066264" MajorTopicYN="N">Datasets as Topic</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006321" MajorTopicYN="N">Heart</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COV-SARS-2</Keyword><Keyword MajorTopicYN="Y">SARS</Keyword><Keyword MajorTopicYN="Y">coronavirus</Keyword><Keyword MajorTopicYN="Y">immune</Keyword><Keyword MajorTopicYN="Y">immunology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32350928</ArticleId><ArticleId IdType="doi">10.1096/fj.202000919</ArticleId><ArticleId IdType="pmc">PMC7267640</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nat Med. 2020 Apr;26(4):453-455</Citation><ArticleIdList><ArticleId IdType="pubmed">32284614</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatol Rehabil. 1976 Aug;15(3):235-8</Citation><ArticleIdList><ArticleId IdType="pubmed">968356</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation><ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation><ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Feb 7;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatology (Oxford). 2006 Jun;45(6):703-10</Citation><ArticleIdList><ArticleId IdType="pubmed">16418198</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Rep. 2019 Nov 19;29(8):2257-2269.e6</Citation><ArticleIdList><ArticleId IdType="pubmed">31747599</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Sci Sports Exerc. 1994 Jul;26(7):857-65</Citation><ArticleIdList><ArticleId IdType="pubmed">7934759</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Rheumatol. 1974;3(2):103-8</Citation><ArticleIdList><ArticleId IdType="pubmed">4608161</ArticleId></ArticleIdList></Reference><Reference><Citation>Trans R Soc Trop Med Hyg. 1983;77(1):24-31</Citation><ArticleIdList><ArticleId IdType="pubmed">6344359</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Immunol. 2018 Feb 16;3(20):</Citation><ArticleIdList><ArticleId IdType="pubmed">29453292</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Cardiol. 2020 Mar 27;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32219356</ArticleId></ArticleIdList></Reference><Reference><Citation>Cytokine Growth Factor Rev. 2014 Dec;25(6):669-79</Citation><ArticleIdList><ArticleId IdType="pubmed">25212897</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Rep. 2018 Jul 31;24(5):1136-1150</Citation><ArticleIdList><ArticleId IdType="pubmed">30067971</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheumatol. 2014 Feb;66(2):319-26</Citation><ArticleIdList><ArticleId IdType="pubmed">24504804</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2008 Dec;4(12):e1000240</Citation><ArticleIdList><ArticleId IdType="pubmed">19079579</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 2015 Nov;42(11):2092-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26428205</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2020 Jun;26(6):1251-1256</Citation><ArticleIdList><ArticleId IdType="pubmed">32168464</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2006 May 29;3:39</Citation><ArticleIdList><ArticleId IdType="pubmed">16729896</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2002 Jun;46(6):1460-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12115175</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation><ArticleIdList><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2020 May;34(5):6027-6037</Citation><ArticleIdList><ArticleId IdType="pubmed">32350928</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101663</Citation><ArticleIdList><ArticleId IdType="pubmed">32289548</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thromb Haemost. 2020 Apr;18(4):844-847</Citation><ArticleIdList><ArticleId IdType="pubmed">32073213</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Mar 20;:105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Rheumatol. 2020 Mar;16(3):155-166</Citation><ArticleIdList><ArticleId IdType="pubmed">32034323</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Res. 1986;5(4):294-304</Citation><ArticleIdList><ArticleId IdType="pubmed">3298467</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2000 Nov 1;165(9):5048-53</Citation><ArticleIdList><ArticleId IdType="pubmed">11046034</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2020 Jun;20(6):669-677</Citation><ArticleIdList><ArticleId IdType="pubmed">32240634</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2016 May 27;474(2):345-350</Citation><ArticleIdList><ArticleId IdType="pubmed">27109480</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 1983 Nov;72(5):1793-800</Citation><ArticleIdList><ArticleId IdType="pubmed">6415117</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Trop Med Parasitol. 1985 Dec;79(6):563-73</Citation><ArticleIdList><ArticleId IdType="pubmed">3834841</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Mar 09;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Inflammopharmacology. 2015 Oct;23(5):231-69</Citation><ArticleIdList><ArticleId IdType="pubmed">26246395</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2020 May 5;172(9):577-582</Citation><ArticleIdList><ArticleId IdType="pubmed">32150748</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2020 Jun 2;172(11):754-755</Citation><ArticleIdList><ArticleId IdType="pubmed">32232419</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Feb 24;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2009 Apr;53(4):1468-75</Citation><ArticleIdList><ArticleId IdType="pubmed">19188392</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Mal Infect. 2020 Jun;50(4):384</Citation><ArticleIdList><ArticleId IdType="pubmed">32240719</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1997 Apr;175(4):871-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9086143</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation><ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Immunol. 2020 May;17(5):533-535</Citation><ArticleIdList><ArticleId IdType="pubmed">32203188</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatology (Oxford). 2007 Jul;46(7):1157-60</Citation><ArticleIdList><ArticleId IdType="pubmed">17478469</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2011 Sep;11(9):677-83</Citation><ArticleIdList><ArticleId IdType="pubmed">21550310</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 1989 Jun;27(6):771-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2757893</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 2008 Mar;35(3):387-93</Citation><ArticleIdList><ArticleId IdType="pubmed">18260176</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84</Citation><ArticleIdList><ArticleId IdType="pubmed">24841269</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatology (Oxford). 2012 Jun;51(6):1061-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22298793</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2006 Feb;54(2):628-34</Citation><ArticleIdList><ArticleId IdType="pubmed">16447241</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2018 Jun;365(3):447-459</Citation><ArticleIdList><ArticleId IdType="pubmed">29438998</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2005 Sep 19;202(6):817-28</Citation><ArticleIdList><ArticleId IdType="pubmed">16157687</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2020 May;80(5):554-562</Citation><ArticleIdList><ArticleId IdType="pubmed">32169481</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Microbiol. 2019 Sep 8;73:529-557</Citation><ArticleIdList><ArticleId IdType="pubmed">31226023</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15351731</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Rheum Dis. 2020 Feb;23(2):197-202</Citation><ArticleIdList><ArticleId IdType="pubmed">31692250</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2015 May 1;194(9):4089-93</Citation><ArticleIdList><ArticleId IdType="pubmed">25821216</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Immunol. 2020 May;17(5):541-543</Citation><ArticleIdList><ArticleId IdType="pubmed">32203186</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 20;43(0):E019</Citation><ArticleIdList><ArticleId IdType="pubmed">32075365</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2007 May 03;4:39</Citation><ArticleIdList><ArticleId IdType="pubmed">17477867</ArticleId></ArticleIdList></Reference><Reference><Citation>J Heart Lung Transplant. 2020 May;39(5):405-407</Citation><ArticleIdList><ArticleId IdType="pubmed">32362390</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Med Virol. 2020 May;30(3):e2107</Citation><ArticleIdList><ArticleId IdType="pubmed">32267987</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2003 Nov;3(11):722-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14592603</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Vaccine Immunol. 2008 Oct;15(10):1497-504</Citation><ArticleIdList><ArticleId IdType="pubmed">18753338</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 2018 Jun;45(6):818-826</Citation><ArticleIdList><ArticleId IdType="pubmed">29545450</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2020 Apr;26(4):506-510</Citation><ArticleIdList><ArticleId IdType="pubmed">32284616</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2020 Apr 10;21(7):</Citation><ArticleIdList><ArticleId IdType="pubmed">32290293</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2018 Mar 22;13(3):e0194868</Citation><ArticleIdList><ArticleId IdType="pubmed">29566060</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2020 Feb 14;94(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">31826992</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001836 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001836 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32350928
|texte= Rethinking the role of hydroxychloroquine in the treatment of COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32350928" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |